All In Biotech

Drug Trial Radar · NCT03888105

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

515

Actual

Start

Nov 13, 2019

Primary completion

Jun 17, 2026

Study completion Dec 15, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Mar 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is researching an investigational drug, odronextamab, in adult patients B-cell non-Hodgkin's lymphoma (B-NHL). The main purpose of this study is to assess the effectiveness of odronextamab in destroying cancer cells and to learn more about the safety of odronextamab. The study is looking at several other research questions, including: * To see if odronextamab works to destroy cancer cells * Side effects that may be experienced by people taking odronextamab * How odronextamab works in the body * How much odronextamab is present in the blood

Conditions

  • B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

  • OdronextamabDrug

    Administered by intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR), as assessed by independent central reviewTime frame: Up to 52 weeks of study treatment
  2. ORR, as assessed by independent central reviewTime frame: Up to 36 weeks of study treatment

Locations

119 sites in 14 countries. Site status is shown where the registry gives one.

  • Rush University Medical Center

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • Norton Cancer Institute

    Louisville, Kentucky

  • Tufts Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey

  • Weill Cornell Medical College New York Presbyterian Hospital

    New York, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • Harold C. Simmons Comprehensive Cancer Center

    Dallas, Texas

  • Border Medical Oncology

    East Albury, New South Wales, Australia

  • Northern NSW Local Health District The Tweed Hospital

    Tweed Heads, South Wales, Australia

  • Epworth Hospital

    East Melbourne, Victoria, Australia

  • North Building

    Frankston, Victoria, Australia

  • Andrew Love Cancer Centre

    Geelong, Victoria, Australia

  • Olivia Newton John Cancer Wellness & Research Centre

    Heidelberg, Victoria, Australia

  • Royal Perth Hospital

    Perth, Western Australia, Australia

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • QEII Health Science Centre - Halifax location

    Halifax, Nova Scotia, Canada

  • Peking University - Third Hospital

    Beijing, China

  • Peking University Cancer Hospital (Beijing Cancer Hospital) (Beijing Institute for Cancer Research)

    Beijing, Beijing Municipality, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Beijing Municipality, China

  • Second Affiliated Hospital - Xinqiao Hospital

    Chongqing, Chongqing Municipality, China

  • Sun Yat-Sen University Cancer Center - Cancer Prevention and Treatment Center, Sun Yat-sen University

    Guangzhou, Guangdong, China

  • The Affiliated Tumor Hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The First Affiliated Hospital - Soochow University

    Suzhou, Jiangsu, China

  • The First Bethune Hospital

    Changchun, Jilin, China

  • The First Affiliated Hospital of Xi 'an Jiaotong University

    Xi'an, Shaanxi, China

  • Shanhai Cancer Center

    Shanghai, Shanghai Municipality, China

  • West China Hospital

    Chengdu, Sichuan, China

  • Tianjin Medical University Cancer Institute

    Tianjin, Tianjin Municipality, China

  • The First Hospital affiliated to the Medical School of Zhejiang University

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Hopital Saint Louis

    Paris, France

Showing 40 of 119 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.